Infections caused by extended-spectrum β-lactamase (ESBL) and carbapenemase producing Gram negative bacteria are an emerging global health problem. For the present study, the clinical isolates (n=58) were collected from two diagnostic centers in Tamil Nadu, India. The bacterial isolates were screened for cefotaxime and meropenem resistance. Further, the presence of ESBL resistant gene CTX-M and carbapenem-resistant genes blaNDM-1, blaOXA-48, blaIMP, blaVIM, blaKPC and integrons were studied. Transconjugation studies and DNA fingerprinting was performed. A total of 58 clinical isolates that included Escherichia coli (n=33), Klebsiella pneumoniae (n=8), Pseudomonas aeruginosa (n=6), Enterobacter cloacae (n=6) and Proteus mirabilis (n=5) were analyzed. MIC results showed that 77.6% (45/58) and 36.2% (21/58) of the clinical isolates were resistant to cefotaxime and meropenem, respectively. The blaCTX-M was present in 34 isolates, the presence of blaNDM-1 in 6 isolates and the blaOXA-48 in 2 isolates. Class 1 integrons were found in 22 isolates and class 2 in 5 isolates. Conjugation studies revealed that 9 CTX-M positive E. coli strains were able to transfer resistance via plasmids to susceptible E. coli AB1157. This study documented the presence of E. coli strains to harbour both CTX-M and NDM-1 gene determinants and plasmid-associated ESBLs were transferable in some E. coli strains.